Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 69.00
Bid: 68.00
Ask: 70.00
Change: 0.00 (0.00%)
Spread: 2.00 (2.941%)
Open: 69.00
High: 69.00
Low: 69.00
Prev. Close: 69.00
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wanda Launches CareLink, New Digital Health App

15 Aug 2018 07:00

RNS Number : 7719X
NetScientific PLC
15 August 2018
 

 

 

NetScientific plc

("NetScientific" or the "Group")

 

Wanda launches new digital health app Wanda CareLink™ with enhanced real-time capabilities on iOS and Android devices

 

London, UK - August 15, 2018 - NetScientific plc ("NetScientific", AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that portfolio company Wanda, which uses machine learning to help healthcare providers to better manage the risk and care of patients, has launched its new digital health application Wanda CareLink™. This application allows the Wanda Patient Management solution to be used on a wide variety of internet-enabled devices including iOS and Android devices. This enhances the ability for patients and doctors alike to improve clinical and financial outcomes.

 

The application is available on the Apple Store and is to become available on Google Play shortly.

 

Commenting on the news, Francois R. Martelet, NetScientific's Chief Executive Officer and Chairman of Wanda, said: "Wanda continues to improve its capabilities to match the needs of the market and its clients, and we believe that it will result in increased traction as healthcare providers realise the value of remote patient monitoring from both a financial and clinical standpoint. We are pleased to see Wanda's progress in strengthening its core offering and look forward to further progress."

 

NetScientific holds a 62% stake on a fully diluted basis in Wanda. The full announcement is included below.

 

For more information, please contact:

 

  NetScientific

François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO

Tel: +44 (0)20 3514 1800

Wanda, Inc.

Bill Basset, CCO

Tel: +1 (0)206 910 0428

Consilium Strategic Communications

Mary-Jane Elliott / Chris Welsh / Laura Thornton

 

 

Tel: +44 (0)20 3709 5700

netscientific@consilium-comms.com

WHIreland (NOMAD and Broker)

Chris Fielding / Jessica Cave / Chris Viggor

Tel: +44 (0)20 7220 1666

 

 

About NetScientific

 

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net

 

 

Predictive Patient Management Platform Expands Real-Time Mobile Capabilities

August 15, 2018 (San Francisco, CA) -- Wanda is pleased to announce the release of its new digital health application Wanda CareLink™. The multi-platform application greatly expands the mobility of the Wanda Patient Management solution to be used on virtually any internet-enabled device including iOS and Android smartphones and tablets. The "bring-your-own-device" approach expands the ability for patients, doctors, and clinicians to improve care plan adherence producing better clinical and financial outcomes. 

The Wanda platform empowers doctors and clinicians with the ability to know when patients will have adverse events before they happen, predicting 90% of rehospitalizations and emergency department visits seven days before they occur. The embedded predictive algorithms identify high-risk patients, alerting doctors and clinicians to the root-causes triggering the adverse events. These insights help clinical teams to assess care plans and proactively manage virtual interventions, which improve patient care plan adherence and resolve the adverse event before it happens.

"Wanda is proving to be a great solution for supporting preventative patient engagement with 74% of patients staying adherent to their care plan," stated William Bassett, Chief Commercial Officer at Wanda. "As high-risk patients are identified, Wanda facilitates better decision making, empowering doctors and clinicians with the real-time insight that will keep patients from preventable emergent situations."

The Wanda application was created from twelve years of research at UCLA, in a collaborative research project including the Medical, Nursing and Engineering Schools. After eight clinical trials yielding nine patents, the machine learning clinical algorithms have shown to predict 90% of adverse events, rehospitalizations and ED visits, seven days before the event will occur. Wanda warns of the pending adverse event detailing the risk triggers for each patient prompting the need for intervention and then facilitates clinical case management.

"Providers and payers can more easily identify and eliminate issues that have made population health and risk-based contracting a challenge," said Ahsan Samiee, Chief Technology Officer at Wanda. "The embedded data science in Wanda can now be used across a range of mobile tools to expand the efficiency of real-time patient care."

 

About Wanda, Inc.

Wanda is dedicated to advancing the effectiveness and efficiency of medicine by using machine learning and modern software applications that empower payers and providers to better manage the risk and care of patients dramatically lowering the cost of care and improving outcomes. More information about Wanda can be found at http://www.yourwanda.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCLLFEITFISLIT
Date   Source Headline
24th Aug 202011:28 amRNSResult of General Meeting
21st Aug 20201:23 pmRNSHolding(s) in Company
21st Aug 202011:47 amRNSIssue of Equity
14th Aug 202010:48 amRNSPDS Announces Closing of $19m Offering
12th Aug 202012:28 pmRNSSofant secures £2.3m funding led by EMV Capital
12th Aug 20207:00 amRNSPDS Announces Pricing of $16.5m Common Stock Offer
11th Aug 202012:27 pmRNSPDS Announces Proposed Offering of Common Stock
7th Aug 20209:32 amRNSPosting of shareholder circular
6th Aug 20202:00 pmRNSHolding(s) in Company
5th Aug 202010:32 amRNSResult of Placing
5th Aug 20208:30 amRNSProposed acquisition and placing
4th Aug 202011:05 amRNSSecond Price Monitoring Extn
4th Aug 202011:00 amRNSPrice Monitoring Extension
27th Jul 20203:06 pmRNSPDS Announces Preclinical Data for PDS0203
14th Jul 20204:20 pmRNSPDS collaborator awarded grant for Versamune
29th Jun 20207:00 amRNSG–Tech Medical completes $6.7m Series A financing
25th Jun 20204:41 pmRNSSecond Price Monitoring Extn
25th Jun 20204:35 pmRNSPrice Monitoring Extension
24th Jun 20205:58 pmRNSHolding(s) in Company
24th Jun 20205:54 pmRNSHolding(s) in Company
24th Jun 20204:09 pmRNSResult of AGM
18th Jun 20204:41 pmRNSSecond Price Monitoring Extn
18th Jun 20204:36 pmRNSPrice Monitoring Extension
18th Jun 202011:05 amRNSSecond Price Monitoring Extn
18th Jun 202011:00 amRNSPrice Monitoring Extension
18th Jun 20209:05 amRNSSecond Price Monitoring Extn
18th Jun 20209:00 amRNSPrice Monitoring Extension
18th Jun 20207:00 amRNSPDS & Farmacore Announce Co-Development-PDS0204
15th Jun 20202:41 pmRNSPDS Announces Initiation of Phase 2 Trial PDS0101
8th Jun 20204:42 pmRNSSecond Price Monitoring Extn
8th Jun 20204:36 pmRNSPrice Monitoring Extension
5th Jun 20209:14 amRNSPDS Announces Trial of its Lead Product, PDS0101
1st Jun 20207:00 amRNSNotice of AGM
13th May 20202:46 pmRNSPDS Reports Results for Q1 2020 & Business Update
1st May 202011:33 amRNSConfirmation of Board Changes
30th Apr 202012:06 pmRNSPDS expands CRADA with National Cancer Institute
27th Apr 20207:00 amRNSPreliminary Results for the year ended 31 Dec 2019
17th Apr 20204:40 pmRNSSecond Price Monitoring Extn
17th Apr 20204:36 pmRNSPrice Monitoring Extension
17th Apr 20202:06 pmRNSSecond Price Monitoring Extn
17th Apr 20202:00 pmRNSPrice Monitoring Extension
16th Apr 20204:40 pmRNSSecond Price Monitoring Extn
16th Apr 20204:35 pmRNSPrice Monitoring Extension
16th Apr 20202:02 pmRNSPDS Initiates Programs for COVID-19, PDS0101 delay
14th Apr 20207:04 amRNSPDS Appoints Ilian Iliev to the Board
31st Mar 20207:00 amRNSBoard Changes
30th Mar 20209:39 amRNSHolding(s) in Company
14th Feb 20203:12 pmRNSHolding(s) in Company
12th Feb 202011:07 amRNSPDS equity issue and related party transaction
11th Feb 20202:24 pmRNSPDS Biotechnology proposed offering

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.